Advanced Systemic Mastocytosis clinical trials at UCLA
2 in progress, 1 open to eligible people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
open to eligible people ages 18 years and up
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Los Angeles, California and other locations
Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Sorry, not accepting new patients
The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who have received and failed or been intolerant to at least one standard approved therapy and/or have no comparable or satisfactory alternative therapy options.
Los Angeles, California and other locations
Last updated: